1). Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol. 2006. 24:2576–82.
Article
2). Boultwood J., Lewis S., Wainscoat JS. The 5q-syndrome. Blood. 1994. 84:3253–60.
Article
3). Mathew P., Tefferi A., Dewald GW, et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood. 1993. 81:1040–5.
4). Pedersen B., Jensen IM. Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients. Leukemia. 1991. 5:566–73.
5). Jaffe ES., Harris NL., Stein H., Vardiman JW. Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality. 1st ed.Lyon: IARC Press;2001. p. 73.
6). Giagounidis AA., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006. 12:5–10.
Article
7). Boultwood J., Fidler C., Strickson AJ, et al. Transcription mapping of the 5q-syndrome critical region: Cloning of two novel genes and sequencing, expression, and mapping of a further six novel cdnas. Genomics. 2000. 66:26–34.
8). Horrigan SK., Arbieva ZH., Xie HY, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood. 2000. 95:2372–7.
Article
9). Pedersen B. 5q(-)survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Leuk Lymphoma. 1998. 31:325–34.